Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-GEMOX in refractory/relapsed CD20-positive diffuse large B-cell lymphoma not eligible for autologous transplantation
2005-002344-26Phase 2Completed
- Sponsor
- Groupe d'Étude des Lymphomes de l'Adulte
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL), sponsored by Groupe d'Étude des Lymphomes de l'Adulte. Primary endpoints: Overall Response Rate at end of 4 cycles and Overall Response Rate at end of treatment (8 cycles). Started Dec 2005; status: completed.
02
Drugs
rituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2005-002344-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002344-26.